DOCSLIB.ORG

A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional EUF-224; No. of Pages 7 E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 1 6 ) X X X – X X X ava ilable at www.sciencedirect.com journa l homepage: www.europeanurology.com/eufocus Bladder Cancer A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study a, b c d e f Noa Davis *, Alexander Shtabsky , Sylvia Lew , Ronny Rona , Ilan Leibovitch , Ofer Nativ , g h i a j Michael Cohen , Yoram Mor , Uri Lindner , Yael Glickman , Haim Matzkin , k l m Alexander Tsivian , Ofer Gofrit , Ofer Yossepovitch a b Micromedic Technologies Ltd., Tel Aviv, Israel; Institute of Pathology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel c d e f Aviv, Israel; Patho-Lab Diagnostics Ltd., Ness Ziona, Israel; Kfar Saba, Israel; Department of Urology, Meir Medical Center, Kfar Saba, Israel; Department g h of Urology, Bnai Zion Medical Center, Haifa, Israel; Department of Urology, HaEmek Medical Center, Afula, Israel; Department of Urology, Sheba Medical i j Center, Tel Aviv, Israel; Department of Urology, Kaplan Medical Center, Rehovot, Israel; Department of Urology, Sourasky Medical Center, Tel Aviv, Israel; k l m Department of Urology, Wolfson Medical Center, Holon, Israel; Department of Urology, Hadassah Medical Center, Jerusalem, Israel; Department of Urology, Rabin Medical Center, Petach Tikva, Israel Article info Abstract Article history: Background: CellDetect is a unique histochemical stain enabling color and morphological discrimination between malignant and benign cells based on differences in metabolic signature. Accepted October 11, 2016 Objective: The objective of the present study was to validate the performance of this assay in a controlled, blinded, multicenter study. Associate Editor: Design, setting, and participants: The study, conducted in nine hospitals, included patients James Catto with documented history of bladder cancer, monitored for urothelial carcinoma (UCC) or scheduled for bladder cancer surgery. Outcome measurements and statistical analysis: Cystoscopy and/or biopsy were used as a Keywords: reference standard to determine sensitivity and specificity. Smears were stained by CellDetect Cancer and interpreted by two cytologists blinded to the patient’s final diagnosis. The findings were Urine cytology compared with those of standard urine cytology and BTA stat. Results and limitations: Two hundred and seventeen voided urine specimens were included. Urothelial cell carcinoma Ninety-six (44%) were positive by histology and 121 (56%) were negative by either cystoscopy or UCC histology. The overall sensitivity of CellDetect was 84%. Notably, the sensitivity for detecting low- Urinary bladder grade nonmuscle-invasive bladder cancer tumors was greater than this of BTA stat (78% vs 54%) CellDetect and more than two-fold higher compared with standard cytology (33%, p 0.05). The specificity was 84% in patients undergoing routine surveillance by cystoscopy. At a median follow-up of 9 mo, 21% of the patients with positive CellDetect and negative reference standard developed UCC, which was significantly higher compared with the 5% of the true negative cases. Limitations include the lack of instrumental urine samples and the lack of patients with nongenitourinary cancers in the study population. Conclusions: This study validates the performance of CellDetect as a urine-based assay to identify UCC in patients with history of bladder cancer. The high sensitivity was maintained across all cancer grades and stages without compromising the assay specificity. Further studies are required to test whether this novel stain can be incorporated in routine bladder cancer surveillance as a noninvasive alternative to cystoscopy. Patient summary: Surveillance of bladder cancer requires frequent invasive procedures. In the present study, we validate the ability of a novel biomarker to accurately identify early-stage tumors in urine specimens for the noninvasive monitoring of patients with history of bladder cancer. # 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Micromedic Technologies Ltd., Kiryat Atidim, Tel Aviv 6158101, Israel. Tel. +972-732753427; Fax: +972-73-2753451. E-mail address: [email protected] (N. Davis). http://dx.doi.org/10.1016/j.euf.2016.10.004 2405-4569/# 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. Please cite this article in press as: Davis N, et al. A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study. Eur Urol Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.10.004 EUF-224; No. of Pages 7 2 E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 1 6 ) X X X – X X X 1. Introduction Adult patients monitored for UCC were consecutively enrolled if they had a documented history of UCC, if at least 4 wk had passed since any treatment or procedure for UCC was performed, and if they were able to Urothelial cell carcinoma (UCC) is the most common provide a spontaneous urine sample. Patients with catheters, neoblad- malignancy in the urinary system [1], with a worldwide der, ileal conduit, or kidney stones, patients under any other cancer prevalence of 2.7 million patients [2] and an annual treatment, or patients with suspicious/positive cystoscopy without a incidence of 429 800 new cases [3]. With up to an 80% subsequent biopsy were excluded. No further selection was performed recurrence rate, UCC often requires a lifelong routine in these patients. surveillance depending on disease severity [4], and is thus Voided urine samples were collected from a first cohort of patients considered one of the most costly cancers in terms of undergoing routine cystoscopic surveillance. To enrich the study with lifetime expenditure per patient [5,6]. Cystoscopy remains positive cases, a second cohort of patients, scheduled for transurethral the reference standard for UCC diagnosis and management, resection (TURBT) or radical cystectomy, was enrolled as well. The notwithstanding its invasive nature and relatively high cost patients from both cohorts had a documented history of bladder cancer. A minimum of 50-ml voided urine was collected from each [7]. The need for noninvasive, accurate, cost-effective participant. For urinalysis, Multistix 10SG (Siemens Healthcare GmbH, markers for UCC surveillance is evident. Erlangen, Germany) was used. Fresh specimens were tested with the Urine cytology is the most frequently used, noninvasive predicate Food and Drug Administration-approved BTA stat (Polymedco assay for UCC detection [8]. However, its low sensitivity, Inc., Cortlandt Manor, NY, USA) according to manufacturer’s instructions particularly in low-grade tumors, remains a major hurdle and an aliquot was separated subsequently for standard urine cytology. [9]. Over the past 2 decades, additional urinary markers The remaining urine volume was treated with a designated fixative and have been developed [10–12]; however, none of them have preserved at 4 8C. Samples were then processed to cytocentrifuge smears been proven sufficiently accurate and cost-effective to be in a central lab and fixed in 96% ethanol. integrated in routine patient management [13]. CellDetect is a novel histochemical staining platform 2.2. Staining allowing color and morphological discrimination between normal and neoplastic cells [14,15]. The discriminative Smears were stained by CellDetect according to manufacturer’s instruc- capacity of the stain is assumingly related to the increased tions (Zetiq Technologies Ltd., Tel Aviv, Israel). Briefly, the CellDetect kit contains a proprietary plant extract and two histological dyes. The metabolic activity inherent in cancer cells. This so called staining procedure includes fixation with 10% trichloroacetic acid, nuclear Warburg Effect, characterized by the aerobic glycolysis of staining with hematoxylin followed by differentiation in HCl/ethanol, malignant tumors, is commonly used in cancer diagnostics conditioning with the plant extract, staining with the red dye, such as tumor imaging using labeled glucose analogues (ie, differentiation in acetic acid/ethanol, and staining with the green dye. positron emission tomography-computed tomography). With CellDetect, the nucleus of the malignant cell is stained in red. CellDetect is composed of a unique plant extract (Ficus The cytoplasm of cancer cells is often stained in pink, especially when elastica) and generic dyes. The active component of the plant cells are arranged in clusters. Normal urothelial or squamous epithelial extract was found to be a member of the proantocyanidin cells typically have a dark purple or green nucleus and greenish family, a class of polyphenols present in a variety of plants. cytoplasm. Inflammatory cells are stained in purple/red, and are While the molecular mechanism is not yet fully elucidated, a distinguishable based on their morphology. series of experiments performed on multiple cell lines All CellDetect stained smears were assessed under a light microscope (Olympus Life Science Solutions, Center Valley, PA, USA) by two showed that the purified active component interacts independent cytologists. Five optional results were assigned: negative, specifically with proteins found in malignant cells, thus reactive/inflammatory, suspicious, highly suspicious, and positive for leading to their specific labeling with the red dye. Benign UCC. These options were implemented based on a practice routinely epithelial cells are counter-stained in green (Fig. 1). In
Load more

Recommended publications
  • Scientific Program
    www.iscort.org.il Scientific Program 08.01.2019 - 12.01.2019, Eilat, Israel The Annual Meeting of The Israeli Society for Clinical Oncology and Radiation Therapy ISCORT wishes to express its gratitude to the following companies הוועדה המארגנת for their support of the 19th ISCORT Annual Meeting: Organizing Committee ISCORT 19 נשיא הכנס: :President פרופ׳ סלומון שטמר Platinum Sponsor Salomon M. Stemmer, MD Roche מזכירת הכנס: :Secretory ד״ר ולריה סמניסטי Gold Sponsor Valeria Semenysty, MD יו"ר הרדיותרפיה: :BMS Radiation Oncology Co-Chair פרופ׳ בן קורן MSD Ben W. Corn, MD הוועדה המדעית Silver Sponsor Scientific Committee ISCORT 19 Astellas יו"ר: פרופ׳ מיכל לוטם Astrazeneca Chairman: Michal Lotem, MD ד"ר אהרון אלון Boehringer Ingelheim Aaron Allen, MD ד"ר נועם אסנה Eli Lilly Noam Asna, MD ד"ר יאיר בר ISI Jair Bar, MD PhD ד"ר יהונתן כהן Novartis Yonathan Cohen, MD PhD פרופ׳ בן קורן Pfizer Ben W. Corn, MD ד"ר אלה עברון Rafa Ella Evron, MD ד"ר דניאלה כץ Daniela Katz, MD פרופ׳ גל מרקל Bronze Sponsor Gal Markel, MD PhD ד"ר אינה אוספובט AbbVie Inna Ospovat, MD ד"ר אביבית פאר Assuta Avivit Peer, MD ד"ר רות פרץ Bayer Ruth Perets, MD PhD Bolpharma ד"ר רפאל פפר Raphael Pfeffer, MD Dexcel Pharma ד"ר קרן רובינוב Keren Rouvinov, MD Isotopia ד"ר יקטרינה שולמן Katerina Shulman, MD Medison ד"ר אמיר זוננבליק Merck Amir Sonnenblick, MD ד"ר מרק ויגודה Nanostring Marc Wygoda, MD ד"ר אלונה זר Neopharm Alona Zer, MD ד"ר אביעד זיק Oncotest-Teva Aviad Zik, MD Perrigo החברה המארגנת Sanofi Organizing Company א.מ.
    [Show full text]
  • Around the Globe Israeli Medical Association No
    Around The Globe Israeli Medical Association No. 16 | June 2011 A word from the chairman Dear Friends, vices to those from evacuated areas who and opinions on professional issues as e are happy to present you had no access to medical care. well as on the unbalanced exposures and with another issue of ‘IMA I had the pleasure of travelling to discussions of political topics concerning around the Globe’ where the UK, and met our Jewish Medical As- Israel in the British scientific Journals. I Wyou can read about the work of the IMA sociation - UK Chapter. I met medical would like to thank the IMA UK Chapter in Israel and abroad. In February, the students affiliated with the IMA and re- for their generous hospitality during my IMA publically announced our launch viewed Neuroscience practice in Israel. time in London. of “a mission to save public medicine,” I attended an evening event hosted by I am excited to inform you that we demanding additional manpower, more Dr. David Katz, the executive chairman have been invited to present Israeli and beds in hospitals, and incentive pay to of the UK Chapter, which was attended Jewish Medicine at the European Par- draw more physicians to the periphery by the local IMA-WF committee group. liament this November. I would like to and to multiple specialties suffering Throughout the evening we discussed thank Dr. Willie Lipschutz, the executive from physician shortages. This struggle issues related to how Israeli medicine chairman of the Belgian Chapter of IMA- is for health and medicine in Israel and is portrayed in British medical journals, WF for organizing the event.
    [Show full text]
  • Israel Endocrine Society
    Israel Endocrine Society Israel Endocrine Society Conference Browse the program for the upcoming event By Session All Sessions By ID 4 By Day Tuesday By Author Aizic, A. - 31 Now Viewing: All Sessions Note: The presenter's name is in bold Registration Tuesday Morning Date: Tuesday, April 9, 2013 Time: 7:30 AM - 8:00 AM Location: Oral Presentations I: Diabetes, Obesity and Metabolism Date: Tuesday, April 9, 2013 Time: 8:00 AM - 10:00 AM Location: Bareket Hall Session Chair: Benjamin Glaser Session Chair: Hannah Kanety 8:00 AM - AMPK corrects ER morphology and function in stressed pancreatic beta-cells via regulation of the ER resident protein DRP1 (ID: 25) Jakob Wikstrom (Israel) Tal Israeli (Israel) Etty Bachar-Wikstrom (Israel) Yafa Ariav (Israel) Erol Cerasi (Israel) Gil Leibowitz (Israel) 8:15 AM - Paradox In Metabolic Homeostasis: AHNAK Knockout Mice Are Resistant To Diet-Induced Obesity And Yet They Display Reduced Insulin Sensitivity (ID: 47) Maya Ramdas (Israel) Chava Harel (Israel) Natalia Krits (Israel) http://www.xcdsystem.com/ies2013/Program/index.cfm[05/04/2013 11:15:55] Israel Endocrine Society Michal Armoni, Rambam Medical Center (Israel) Eddy Karnieli, Institute of Endocrinology, Metabolism and Diabetes (Israel) 8:30 AM - Neonatal Wolfram syndrome: novel De-novo dominant mutation presenting as an unusual clinical phenotype (ID: 52) Abdulsalam Abu-Libdeh, Hadassah Hebrew University Hospital (Israel) 8:45 AM - Importance of maintaining redox potential balance in the development of type 2 diabetes (ID: 61) Tovit Rosenzweig,
    [Show full text]
  • Recurrent Deep Venous Thrombosis in a Patient with Agenesis of Inferior Vena Cava
    International Journal of General Medicine Dovepress open access to scientific and medical research Open Access Full Text Article CASE REPORT Recurrent deep venous thrombosis in a patient with agenesis of inferior vena cava William Nseir1 Background: Agenesis of the inferior vena cava (IVC) as a cause of recurrent deep vein Mahmud Mahamid1 thrombosis (DVT) is uncommon. Zuhair Abu-Rahmeh2 Case: A 33-year-old male with no family history of thrombophilia, who had experienced mul- Arieh Markel3,4 tiple recurrent episodes of DVT over a 15-year period of unknown cause, was admitted into our hospital because of cellulitis in the right leg. Computer tomography with contrast of the 1Department of Internal Medicine, 2Radiology Department, Holy abdomen showed an absence of IVC. Family Hospital, Nazareth, Israel; Conclusion: Congenital absence of the IVC could be a rare risk factor for idiopathic DVT, 3 Department of Internal Medicine A, especially in young individuals. Haemek Medical Center, Afula, Israel; 4Technion, Faculty of Medicine, Haifa, Keywords: deep vein thrombosis, agenesis, inferior vena cava Israel Background Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, has an incidence of 1 to 3 per 1000 individuals per year in Western populations.1 Congenital anomalies of the inferior vena cava (IVC) are uncommon, and have been associated with the development of venous thrombosis of the lower limbs.2 Congenital anomalies of the IVC has been reported as a risk factor for DVT, especially in individuals ,30 years old, and a concomitant thrombophilic disorder has been found in such individuals.3 We report a case of recurrent DVT in a 33-year-old man with agenesis of the IVC.
    [Show full text]
  • The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity
    S7 - Prognosis and Outcome in Heart Failure The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity Ayelet Itzhaki-Alfia 1, Jonathan Leor 1,Shiri Netser1, Leonid Sternik 2, Dan Spiegelstein 2, David Mishaly 2, Jacob Lavee 2, Ehud Raanani 2,Barbash Israel M3 1 Neufeld Cardiac Research Institute, Sackler Faculty of Medicine,Tel-Aviv University, 2 Department of Cardiothoracic Surgery, 3 Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 37 S7 - Prognosis and Outcome in Heart Failure The Impact of the NT-proBNP Assay in the Emergency Department on the Diagnosis of Heart Failure and on Outcomes in Patients Admitted for Dyspnea: A Prospective Randomized Placebo-controlled Double-center Trial (BNP4EVER) Simcha Meisel 1, Margarita Medvedovski 2, Moshe Sharist 3, Jalal Ashkar 2,Pavel Pschianski2, Michael Glikson 4, Shmuel Bar Haim 3, Michael Shochat 1, David Blondheim 1, Avraham Shotan 1 1 Heart Institute, Hillel Yaffe Medical Center, 2 Emergency Department, Hillel Yaffe Medical Center, Hadera, 3 Emergency Department, Assaf Harofeh Medical Center, Zerifin, 4 Heart Institute, Chaim Sheba Medical Center, Hadera, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 38 S7 - Prognosis and Outcome in Heart Failure Echocardiographic and Plasma N-Terminal Pro-B Type Natriuretic Peptide Evaluation During Pregnancy in Patients with Preexisting Dilated Cardiomyopathy Alex Blatt 1,Ilya Litovchik1, Ricardo
    [Show full text]
  • Curriculum Vitae – Barak Zafrir
    Curriculum Vitae – Barak Zafrir PERSONAL DETAILS Date Prepared: November 2016 Name: BARAK ZAFRIR Office Address: Cardiovascular Department, Lady Davis Carmel Medical Center 7 Michal St., Haifa, Israel. Home Address: 6/6 Moshe Dayan St. , Kiryat Tiveon , Israel Phone: +972-0522541577 Email: [email protected] FAX: +972-99560390 Place of Birth: ISRAEL Date of Birth June 11, 1974 Marital Status Married; 2 Children ACADEMIC DEGREES Faculty of Medicine, Technion, 1996-2002 M.D Medicine Israel Institute of Technology, Haifa, Israel. PROFESSIONAL EXPERIENCE 2015-present Director, Cardiac Prevention and Rehabilitation Service Carmel Medical Center, Haifa, Israel 2013-present Preventive Cardiology / Lipid Clinics (a) Carmel Medical Center, Haifa, Israel. (b) Acre, Clalit Health Services, Haifa and Western Galilee District. 1 2012-2013 Advanced Clinical/Research Fellowship: Preventive Cardiology and Cardio-metabolic Diseases Brigham & Women's Hospital, Harvard Medical School, Boston, USA, [Fellowship Director: Jorge Plutzky M.D] 2010-present Staff Cardiologist Cardiovascular Department, Carmel Medical Center, Haifa, Israel 2004-2010 Residency and Fellowship: Internal Medicine and Cardiology Carmel Medical Center, Haifa, Israel. 2003 Internship: Medicine and Surgery HaEmek Medical Center, Afula, Israel. PROFESSIONAL COURSES Oct. 2016 Advanced Course on Familial Hypercholesterolemia, European Atherosclerosis Society, Greece Dec. 2015 Hyperlipidemia Academy, Amgen Co., Geneva, Switzerland. Nov. 2014 Cardiopulmonary Exercise Testing Training Course,
    [Show full text]
  • Scientific Program
    The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2,
    [Show full text]
  • The Peres Center for Peace, Tel-Aviv April 12Th, 2019
    April 12th, 2019 The Peres Center for Peace, Tel-Aviv BREAST CANCER INNOVATIONS The Israeli Society for Clinical Oncology and Radiation Therapy and Roche are Pleased to Invite You to an Enriching and Educating Meeting with our Distinguished Guest Speaker: Prof. Charles E. Geyer Please Send the Attached Registration Form to A.M Knasim No Later than April 1st 2019 E-mail: [email protected] Tel: 03-6081520 Fax: 03-6081522 Prof. Charles E. Geyer Friday, 12th April 2019 • Professor of Medicine 08:00-09:00 Welcome Reception • Harrigan, Haw, Luck Families Chair in Cancer Research 09:00-09:10 Opening Remarks • Virginia Commonwealth University, Massey Dr. Noa Efrat Ben-Baruch Cancer Center Head, Israeli Breast Cancer Group • Associate Director of Clinical Research Head, Department of Oncology Kaplan Medical Center Charles E. Geyer, Jr. is Professor of Medicine and the Harrigan, Haw, Luck Families Chair in Cancer Research at Virginia Commonwealth University Massey Chairmen: Dr. Georgeta Fried Cancer Center, an NCI-designated Cancer Center. He serves as Associate Director Head Breast Cancer Unit of Clinical Research for the Massey Cancer Center with oversight responsibility Rambam Medical Center for all cancer-related clinical research activities within the Center. Prof. Geyer Dr. Margarita Tokar has devoted most of his academic career on the design and conduct of multi- institutional, phase III clinical trials in breast cancer with a particular focus on Senior Oncologist the development of HER2 targeted therapies. He has served in several leadership Soroka University Medical Center positions for multi-institution research initiatives. These include vice-chair of the 09:10-09:30 Personalized Nanothechnologies in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Committee Management of Breast Cancer from 1999 until 2007, Associate Director of Medical Affairs from 2002 to 2006 and Director of Medical Affairs for NSABP from 2006 to 2011.
    [Show full text]
  • APF Newsletter, Winter 2006 – 2007
    Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs.
    [Show full text]
  • The IFSO Global Registry 5Th IFSO Global Registry Report 2019
    The IFSO Global Registry 5th IFSO Global Registry Report 2019 Prepared by Almino Ramos MD MSc PhD FACS FASMBS Lilian Kow BMBS PhD FRACS Wendy Brown MBBS PhD FACS FRACS Richard Welbourn MD FRCS John Dixon PhD FRACGP FRCP Edin Robin Kinsman BSc PhD Peter Walton MA MB BChir MBA FRCP IFSO & Dendrite Clinical Systems The International Federation for the Surgery of Obesity and Metabolic Disorders Fifth IFSO Global Registry Report 2019 Prepared by Almino Ramos MD MSc PhD FACS FASMBS Lilian Kow BMBS PhD FRACS Wendy Brown MBBS PhD FACS FRACS Richard Welbourn MD FRCS John Dixon PhD FRACGP FRCP Edin Robin Kinsman BSc PhD Peter Walton MA MB BChir MBA FRCP IFSO & Dendrite Clinical Systems The International Federation for the Surgery of Obesity and Metabolic Disorders operates the IFSO Global Registry in partnership with Dendrite Clinical Systems Limited. IFSO gratefully acknowledge the assistance of Dendrite Clinical Systems for: • building, maintaining & hosting the web registry • data analysis and • publishing this report Dendrite Clinical Systems Ltd maintains the following United Kingdom and GDPR-compliant Information Governance and Data Security Certificates: • Registration with the UK Government Information Commissioner’s Office (ICO) • NHS Data Security & Protection Toolkit (ODS code 8HJ38) • Cyber Essentials Plus (Registration number QGCE 1448) • G-Cloud 11 (Framework reference RM1557.11) This document is proprietary information that is protected by copyright. All rights reserved. No part of this document may be photocopied, stored in a retrieval system, transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of the publishers and without prior written consent from IFSO and Dendrite Clinical Systems Limited.
    [Show full text]
  • Prof. Ayala Pollack MD Ayala Pollack, MD, Professor of Ophthalmology
    Prof. Ayala Pollack MD Ayala Pollack, MD, Professor of Ophthalmology from the Hebrew University- Hadassah Medical School, Jerusalem. Until recently she was the Chairperson of the Eye Department, Kaplan Medical Center, the Head of the Eye Research Laboratory and the Director of Ophthalmology Clinical Trials Unit, at Kaplan Medical Center, Rehovot, affiliated to Hebrew University- Hadassah Medical School, Prof. Ayala Pollack graduated medical school at the Tel Aviv University Sackler Medical School and completed residency at Kaplan Medical Center. Spent two years of Research and Clinical Fellowship in Vitreo-Retinal Diseases with famous late Paul Henkind at Montefiore Medical Center, Albert Einstein Medical School New York. In l997 became the Chairperson of the Eye Department, Kaplan Medical Center, Main fields of interest are retinal diseases. Her famous unique clinical pioneering research relates to the course of maculopathy following cataract surgery in particular in the diseases age-related macular degeneration and diabetic retinopathy. She published numerous papers in the most prestigious journals, was invited as guest speaker, gave numerous presentations in meetings all over the world. Her work was rewarded for Excellent Papers presented at conferences and meetings. Involved in multicenter clinical trials, participated in many of the most important studies related to age-related macular degeneration (AMD), diabetic retinopathy and vein occlusion. As a retinal surgeon, very much interested in research related to retinal detachment.
    [Show full text]
  • Sarah Shimoni, MD
    1 Sara Shimoni, MD December 2020 Sarah Shimoni, MD 1. CURRICULUM VITAE December 2020 A. 1. Personal data Family status: married Number of children: 5 Permanent address: Hish st 18, Rehovot, Isreal Home phone number: 08-6339231 Work phone number: 08-9440144 Fax: 08-9440145 E-mail: [email protected]; [email protected] 2. Academic education 1985 Hebrew University, Hadassah Medical School, Jerusalem, B Med Sc. 1990 Hebrew University, Hadassah Medical School, Jerusalem, MD. 1988 Kaplan Medical Center, Rehovot, Rotating internship. 1989-90 Kaplan Medical Center, Rehovot, Residency Internal Medicine. 1990-91 The Weizmann Institute of Science, Department of Cell Biology, Rehovot. Research Fellow. 1991-1992 Rabin Medical Center, Campus Beilinson, Residency Internal Medicine . 1993 Certified specialist in Internal Medicine, Ministry of Health, Israel. 1993-5 Kaplan Medical Center, Heart Institute, Rehovot, Fellow, Cardiology. 1995 Certified specialist in Cardiology, Ministry of Health, Israel. 1998-2000 Baylor College of Medicine, Houston, Texas, USA. Fellow, Echocardiography. 2000- 2005 Kaplan Medical Center, Heart Institute, Senior Cardiologist and consultant Physician in charge, echocardiography service. 2005 Head of non invasive cardiology, Heart Institute, Kaplan Medical Center. - 3. Appointments in the Hebrew University 1/10/2000 Instructor, Internal Medicine (Cardiology), Hebrew University, Hadassah Medical School, Jerusalem. 1/4/2003 Lecturer, Internal Medicine (Cardiology), Hebrew University, Hadassah Medical School, Jerusalem. 4/2010 Senior Lecturer ( clinical), Internal Medicine (Cardiology), Hebrew University, Hadassah Medical School, Jerusalem 9/2017 Associate Professor of Medicine, Internal Medicine (Cardiology), Hebrew University, Hadassah Medical School, Jerusalem 4. Additional Functions at the Hebrew University 2006 - Internal medicine 4th year final exam committee. 2004-2017 Student tutor in cardiology department 2015-participating in the OSCE exams 2018-Academic coordinator in Kaplan Medical Center 6.
    [Show full text]